| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Impairment loss | - | 9,926 | - | - |
| Total other income (expense), net | 7,841 | -1,806 | 8,072 | -1,453 |
| Loss before income taxes | -7,509 | -21,519 | -11,723 | -18,532 |
| Benefit from income taxes | -683 | -2,263 | 176 | -3,838 |
| Net loss from consolidated operations | -6,826 | -19,256 | -11,899 | -14,694 |
| Net loss attributable to noncontrolling interests | -218 | -299 | -369 | -46 |
| Net loss attributable to fulgent | -6,608 | -18,957 | -11,530 | -14,648 |
| Weighted average number of shares outstanding, basic, total | 30,749,000 | 30,544,000 | 30,832,000 | 30,416,000 |
| Weighted average number of shares outstanding, diluted, total | 30,749,000 | 30,544,000 | 30,832,000 | 30,416,000 |
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)